H.C. Wainwright bullish on Vivani following positive semaglutide implant data

H.C. Wainwright notes that Vivani Medical (VANI) has announced positive preclinical data for NPM-139, a subdermal semaglutide implant being developed for chronic weight management. In the firm’s view, the preclinical data validates the versatility of the company’s NanoPortal technology platform. Management noted that the ongoing Phase 1 trial of NPM-115 is on track to report topline data in mid-2025, which would provide insights to support further development of NPM-115 as well as NPM-139. H.C. Wainwright reiterate a Buy rating on the shares with a price target of $4.